Spinraza (Nusinersen) Access Update: What Providers and Prescribers Need to Know in 2026

The spinal muscular atrophy treatment landscape has undergone significant changes in recent months. On March 30, 2026, the FDA approved the High Dose Regimen of Spinraza (nusinersen), offering clinicians a new dosing option backed by the DEVOTE trial. Simultaneously, the November 2025 approval of Itvisma (intrathecal onasemnogene abeparvovec) for patients aged 2 and older has further expanded the therapeutic toolkit available to SMA specialists.

For prescribers managing SMA patients, these changes create new clinical decision points, modified prior authorization requirements, and updated insurer coverage policies to navigate. This guide summarizes the key updates every SMA provider needs to know in 2026.

The 2026 High-Dose Spinraza Approval: Clinical Implications

The FDA's March 30, 2026 approval of the High Dose Regimen of Spinraza was supported by data from the DEVOTE Phase 2/3 trial. The high-dose regimen comprises:

Loading phase: Two 50 mg/5 mL doses administered 14 days apart (accelerated vs. the 4-dose, ~60-day low-dose loading schedule)

Maintenance phase: 28 mg/5 mL injections every four months (equivalent frequency to the 12 mg maintenance schedule)

In the pivotal DEVOTE Part B cohort, treatment-naive infants with infantile-onset SMA receiving the high-dose regimen showed a mean CHOP-INTEND improvement of 26.19 points at six months versus a prespecified sham control group. The DEVOTE trial enrolled 145 participants across ages and SMA types at approximately 42 sites worldwide.

The safety profile of the high-dose regimen was consistent with the established profile for low-dose Spinraza. Clinicians should note that thrombocytopenia and coagulation monitoring requirements remain the same — platelet counts and coagulation testing must be performed at baseline and before each administration.

Clinical Decision Points: When to Consider High-Dose vs. Low-Dose Spinraza

Both regimens are now approved for pediatric and adult SMA patients. Key considerations when choosing between them:

Treatment-naive patients: The accelerated 2-dose loading phase of the high-dose regimen may offer advantages for early intervention, particularly in symptomatic infantile-onset SMA where time-to-treatment is critical.

Patients on low-dose who have plateaued: The DEVOTE and ONWARD trials demonstrated that switching patients who have plateaued on 12 mg to the higher dose may produce additional motor function gains.

Patients with scoliosis or post-spinal surgery: These patients may show different response patterns. The DEVOTE trial noted that patients requiring scoliosis surgery showed temporary functional decline that subsequently stabilized or improved.

Updated Monitoring Requirements for Spinraza in 2026

Per the updated prescribing information (last revised March 2026), the monitoring requirements before each Spinraza dose include:

Platelet count and coagulation laboratory testing (baseline and prior to each dose)

Quantitative spot urine protein testing — preferably first-morning urine — at baseline and prior to each dose

If urinary protein concentration >0.2 g/L: consider repeat testing and further evaluation before proceeding with administration

Growth monitoring (height) for infants receiving Spinraza, given the potential for reduced growth

Evolving Insurer Policies: What Prescribers Must Document

Prior authorization for Spinraza is required across virtually all commercial plans, Medicare, and most Medicaid programs. The most comprehensive coverage submissions include:

Confirmed genetic diagnosis: documentation of SMN1 deletion or mutation (5q SMA)

SMN2 copy number documentation

SMA type classification and clinical severity documentation

Baseline functional assessment using validated scales (CHOP-INTEND, HFMSE, RULM as appropriate)

For renewal: documented evidence of clinical benefit (stable or improved function scores at each assessment)

Cigna's coverage policy (effective August 2025) specifically requires prior authorization and approval in 4-month intervals aligned with maintenance dosing. Some insurers are now also evaluating concurrent use of multiple SMA therapies — ensure your documentation clarifies that the patient is receiving monotherapy.

The Expanding Competitive Landscape: Itvisma and Risdiplam

The November 2025 approval of Itvisma (intrathecal onasemnogene abeparvovec, Novartis) for patients aged 2 and older has created a meaningful new option, particularly for patients who have plateaued on ongoing SMN2-modifying therapies. Real-world data and indirect comparison analyses presented at the 2026 MDA Conference suggest similar motor outcomes between Itvisma and continued Spinraza or risdiplam.

Risdiplam (Evrysdi) continues to gain share as the only oral SMA therapy, offering significant compliance advantages for patients who find the injection schedule burdensome. Indirect comparisons published in 2026 suggest risdiplam may be associated with longer survival and higher motor function response rates in Type 1 SMA patients compared to nusinersen, though head-to-head trials have not been conducted.

Specialty Distribution and Administration Logistics

Spinraza continues to be distributed through specialty pharmacies directly to treatment centers. Administration requires intrathecal delivery via lumbar puncture by trained personnel. Key logistical considerations:

Prepare with ultrasound or fluoroscopic guidance for younger patients or those with spinal deformities

Remove 5 mL CSF prior to injection; administer as intrathecal bolus over 1-3 minutes

Use vial strength corresponding to prescribed dose; do not combine vials of different strengths

Allow vial to warm to room temperature (25°C/77°F) before administration; do not use external heat sources

How medfinder Supports SMA Providers

For providers whose patients are struggling to navigate the complex access pathways for Spinraza and other SMA therapies, medfinder for providers offers a paid service that helps patients locate treatment resources, coordinate specialty pharmacy access, and reduce the administrative burden on your practice. Referring patients to medfinder frees your team to focus on clinical management while medfinder handles the logistics.

Also see our provider guide: How to Help Your Patients Find Spinraza in Stock.